Bernard Le Bonniec

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6430669/publications.pdf

Version: 2024-02-01

69 papers	2,138 citations	236925 25 h-index	233421 45 g-index
74 all docs	74 docs citations	74 times ranked	2026 citing authors

#	Article	IF	Citations
1	Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. European Journal of Pharmacology, 2020, 866, 172798.	3.5	10
2	The Immunomodulatory Effect of IrSPI, a Tick Salivary Gland Serine Protease Inhibitor Involved in Ixodes ricinus Tick Feeding. Vaccines, 2019, 7, 148.	4.4	16
3	Modified ROTEM for the detection of rivaroxaban and apixaban anticoagulant activity in whole blood. European Journal of Anaesthesiology, 2019, 36, 449-456.	1.7	22
4	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. Hematologie, 2019, 25, 233-247.	0.0	0
5	Strategies of neutralization of the direct oral anticoagulants effect: review of the literature. Annales De Biologie Clinique, 2019, 77, 67-78.	0.1	1
6	Treprostinil treatment decreases circulating platelet microvesicles and their procoagulant activity in pediatric pulmonary hypertension. Pediatric Pulmonology, 2019, 54, 66-72.	2.0	13
7	FXa-Î±2-Macroglobulin Complex Neutralizes Direct Oral Anticoagulants Targeting FXa In Vitro and In Vivo. Thrombosis and Haemostasis, 2018, 118, 1535-1544.	3.4	7
8	Thrombin generation test: A reliable tool to evaluate the pharmacodynamics of vitamin K antagonist rodenticides in rats. Pesticide Biochemistry and Physiology, 2018, 146, 19-24.	3.6	3
9	Ticagrelor reversal:in vitroassessment of four haemostatic agents. Journal of Clinical Pathology, 2017, 70, 733-739.	2.0	14
10	Pulsed cavitational therapy using high-frequency ultrasound for the treatment of deep vein thrombosis in an in vitro model of human blood clot. Physics in Medicine and Biology, 2017, 62, 9282-9294.	3.0	5
11	Gestational age-related patterns of AMOT methylation are revealed in preterm infant endothelial progenitors. PLoS ONE, 2017, 12, e0186321.	2.5	12
12	Notice of Removal: Evaluation of a new non-invasive ultrasonic device for venous recanalization: Assessment of feasibility and safety of thrombotripsy at 2.25 MHz in an in vitro model of recent venous thrombosis. , 2017, , .		0
13	Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban. Thrombosis and Haemostasis, 2015, 114, 78-86.	3.4	34
14	Multimodal assessment of nonâ€specific hemostatic agents for apixaban reversal. Journal of Thrombosis and Haemostasis, 2015, 13, 426-436.	3.8	43
15	Thrombin. , 2013, , 2915-2932.		5
16	Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. International Journal of Cardiology, 2013, 168, 4228-4233.	1.7	96
17	Reversal of anticoagulant effects of apixaban with non-specific prohaemostatic agents: an in vitro study. European Heart Journal, 2013, 34, P4854-P4854.	2.2	0
18	Large-Scale Chromatin Immunoprecipitation with Promoter Sequence Microarray Analysis of the Interaction of the NSs Protein of Rift Valley Fever Virus with Regulatory DNA Regions of the Host Genome. Journal of Virology, 2012, 86, 11333-11344.	3.4	26

#	Article	IF	Citations
19	Recombinant activated factor VII and prothrombin complex concentrates have different effects on bleeding and arterial thrombosis in the haemodiluted rabbit. British Journal of Anaesthesia, 2012, 108, 586-593.	3.4	5
20	A motif within the N-terminal domain of TSP-1 specifically promotes the proangiogenic activity of endothelial colony-forming cells. Biochemical Pharmacology, 2012, 84, 1014-1023.	4.4	17
21	Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model. Anesthesiology, 2012, 116, 94-102.	2.5	250
22	Recombinant activated factor VII does not reduce bleeding in rabbits treated with aspirin and clopidogrel. Thrombosis and Haemostasis, 2010, 104, 823-830.	3.4	11
23	Plasminogen Activators from Snake Venoms. , 2010, , 371-392.		2
24	Characterization of a homozygous Gly11Val mutation in the Gla domain of coagulation factor X. Thrombosis Research, 2009, 124, 144-148.	1.7	4
25	Thrombin bound to a fibrin clot confers angiogenic and haemostatic properties on endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2008, 12, 975-986.	3.6	47
26	Platelet Factor 4 (CXCL4) Seals Blood Clots by Altering the Structure of Fibrin. Journal of Biological Chemistry, 2007, 282, 710-720.	3.4	54
27	STRUCTUREâ€“FUNCTION RELATIONSHIP IN THE PLASMINOGEN ACTIVATOR ISOLATED FROM THE VENOM OFTRIMERESURUS STEJNEGERI. Toxin Reviews, 2007, 26, 1-24.	3.4	1
28	The Î³-carboxyglutamic acid domain of anticoagulant protein S is involved in activated protein C cofactor activity, independently of phospholipid binding. Blood, 2005, 105, 122-130.	1.4	33
29	Control of the coagulation system by serpins. FEBS Journal, 2005, 272, 4842-4851.	4.7	117
30	Purification and initial characterization of a novel protein with factor Xa activity from Lonomia obliqua caterpillar spicules. Journal of Mass Spectrometry, 2005, 40, 405-412.	1.6	16
31	Thrombin-activable Factor X Re-establishes an Intrinsic Amplification in Tenase-deficient Plasmas. Journal of Biological Chemistry, 2005, 280, 41352-41359.	3.4	21
32	Inherited factor VII deficiency: identification of two novel mutations (A191V and T239P) in the catalytic domain. Thrombosis Research, 2005, 116, 115-120.	1.7	6
33	The Elusive Role of the Potential Factor X Cation-binding Exosite-1 in Substrate and Inhibitor Interactions. Journal of Biological Chemistry, 2004, 279, 3671-3679.	3.4	15
34	Low Molecular Weight Fucoidan and Heparin Enhance the Basic Fibroblast Growth Factor-Induced Tube Formation of Endothelial Cells through Heparan Sulfate-Dependent Î±6 Overexpression. Molecular Pharmacology, 2003, 64, 696-702.	2.3	71
35	Characterization of the Specificity of Arginine-Specific Gingipains fromPorphyromonas gingivalisReveals Active Site Differences between Different Forms of the Enzymesâ€. Biochemistry, 2003, 42, 11693-11700.	2.5	29
36	Determination of the P1â€², P2â€² and P3â€² subsite-specificity of factor Xa. International Journal of Biochemistry and Cell Biology, 2003, 35, 221-225.	2.8	17

#	Article	IF	Citations
37	Molecular Determinants of the Mechanism Underlying Acceleration of the Interaction between Antithrombin and Factor Xa by Heparin Pentasaccharide. Journal of Biological Chemistry, 2002, 277, 15971-15978.	3.4	23
38	Interaction of heparin with internally quenched fluorogenic peptides derived from heparin-binding consensus sequences, kallistatin and anti-thrombin III. Biochemical Journal, 2002, 366, 435-446.	3.7	18
39	The Stratagem Utilized by the Plasminogen Activator from the Snake Trimeresurus stejnegeri To Escape Serpins. Biochemistry, 2002, 41, 8478-8484.	2.5	21
40	Mapping of the Catalytic Groove Preferences of Factor Xa Reveals an Inadequate Selectivity for Its Macromolecule Substrates. Journal of Biological Chemistry, 2002, 277, 20527-20534.	3.4	55
41	Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects. British Journal of Clinical Pharmacology, 2002, 53, 147-154.	2.4	4
42	Structure of a Serpin-Enzyme Complex Probed by Cysteine Substitutions and Fluorescence Spectroscopy. Biophysical Journal, 2001, 80, 491-497.	0.5	8
43	Electrostatic Steering and Ionic Tethering in the Formation of Thrombinâ˜'Hirudin Complexes:â€‰ The Role of the Thrombin Anion-Binding Exosite-I. Biochemistry, 2001, 40, 4972-4979.	2.5	49
44	Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the Î³-carboxyglutamic acid-rich domain. Biochemical Journal, 2001, 360, 499-506.	3.7	15
45	The dual role of thrombinâ€™s anion-binding exosite-I in the recognition and cleavage of the protease-activated receptor 1. FEBS Journal, 2001, 268, 70-77.	0.2	37
46	Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the Î³-carboxyglutamic acid-rich domain. Biochemical Journal, 2001, 360, 499.	3.7	10
47	The Role of Glu192 in the Allosteric Control of the S2â€² and S3â€² Subsites of Thrombin. Journal of Biological Chemistry, 2000, 275, 809-816.	3.4	15
48	Cleaved antitrypsin polymers at atomic resolution. Protein Science, 2000, 9, 417-420.	7.6	73
49	Une histoire d'arroseur arrosÃ© : dans la cascade, c'est la thrombine qui module la thrombomoduline.. Medecine/Sciences, 2000, 16, 964.	0.2	0
50	Topology of the Stable Serpin-Protease Complexes Revealed by an Autoantibody That Fails to React with the Monomeric Conformers of Antithrombin. Journal of Biological Chemistry, 1999, 274, 4586-4593.	3.4	27
51	Thrombomodulin Modulates the Mitogenic Response to Thrombin of Human Umbilical Vein Endothelial Cells. Thrombosis and Haemostasis, 1998, 79, 848-852.	3.4	25
52	Lonomia obliqua Caterpillar Spicules Trigger Human Blood Coagulation via Activation of Factor X and Prothrombin. Thrombosis and Haemostasis, 1998, 79, 539-542.	3.4	56
53	Intrinsic Specificity of the Reactive Site Loop of Î±1-Antitrypsin, Î±1-Antichymotrypsin, Antithrombin III, and Protease Nexin I. Journal of Biological Chemistry, 1997, 272, 16268-16273.	3.4	37
54	Allosteric modulation of the activity of thrombin. Biochemical Journal, 1997, 321, 361-365.	3.7	14

#	Article	IF	Citations
55	Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease. Journal of Molecular Biology, 1997, 265, 344-362.	4.2	55
56	The thrombin E192Q-BPTI complex reveals gross structural rearrangements: implications for the interaction with antithrombin and thrombomodulin. EMBO Journal, 1997, 16, 2977-2984.	7.8	81
57	Characterization of the P2â€˜ and P3â€˜ Specificities of Thrombin Using Fluorescence-Quenched Substrates and Mapping of the Subsites by Mutagenesis,. Biochemistry, 1996, 35, 7114-7122.	2.5	90
58	Role of the P2 Residue in Determining the Specificity of Serpins. Biochemistry, 1996, 35, 11461-11469.	2.5	44
59	Heparin enhances the catalytic activity of des-ETW-thrombin. Biochemical Journal, 1996, 315, 77-83.	3.7	3
60	Identification of Residues in Thrombin-Modulating Interactions with Antithrombin III and .alpha.1-Antitrypsin. Biochemistry, 1995, 34, 12241-12248.	2.5	54
61	Mapping of the Thrombin des-ETW Conformation by Using Site-Directed Mutants of Hirudin. Evidence for the Induction of Nonlocal Modifications by Mutagenesis. Biochemistry, 1994, 33, 3959-3966.	2.5	16
62	Contribution of interactions with the core domain of hirudin to the stability of its complex with thrombin. Biochemical Journal, 1994, 298, 507-510.	3.7	10
63	[21] Protein C activation. Methods in Enzymology, 1993, 222, 359-385.	1.0	62
64	Glu-192----Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7371-7375.	7.1	159
65	Analysis of ligand-binding data without knowledge of bound or free ligand molar concentration. Analytical Biochemistry, 1988, 174, 280-290.	2.4	2
66	Functional identification of t-PA in crude and purified systems. Thrombosis Research, 1988, 50, 123-130.	1.7	0
67	Functional identification of t-PA in crude and purified systems. Thrombosis Research, 1988, 49, 123-130.	1.7	2
68	Measurement of glycated albumin in diabetic patients by biospecific affinity chromatography. Biomedical Applications, 1987, 419, 75-83.	1.7	9
69	Proteolytic Derivatives of Thrombin. Annals of the New York Academy of Sciences, 1986, 485, 16-26.	3.8	31